World Neem Extract Market is expected to reach $2.04 Billion by 2022; Finds New Report

World Neem Extract Market - Opportunities and Forecasts, 2015 - 2022, the world neem extract market is expected to generate a revenue of $2.04 billion by 2022, with a CAGR of 17.4% from 2016 to 2022. In 2015, Asia-Pacific was the highest revenue-generating region, accounting for 51.8% share of the overall neem extract market revenue. In the same year, the agriculture segment occupied a prominent share among the different application segments.

Increased R&D and study in the field of neem has resulted in growing awareness about the efficacy of different parts of a neem tree, thus making it an important ingredient in several organic food and cosmetics products. Based on application, the world neem extract market is categorized into agriculture, personal care, pharmaceutical, and animal feed. In 2015, the personal care segment contributed approximately 1/7th of the overall neem extract market revenue and is estimated to grow at a CAGR of 19.6% during the forecast period. The growth is primarily attributed to increased awareness among consumers about the adverse effects of chemical-based personal care products, leading them to shift towards organic products. Pharmaceutical segment, which accounted for around 8.9% market share in 2015, is expected to witness a double-digit growth over the analysis period, owing to growing inclination of consumers toward Ayurveda and natural treatment of diseases without any side effects.

By geography, APAC is the major contributor in the neem extract market. It is expected to be the highest revenue-generating region during the forecast period. Widespread awareness about the benefits of neem have resulted in huge demand of neem in the European and North American markets. North America is one of the largest importers of neem extract. However, Europe is likely to grow at a rapid rate with a CAGR of 20.3%. The regions are further bifurcated into major countries, such as the U.S., Canada, and Mexico in North America; U.K., Germany, France and Rest of Europe in Europe; India, China, Japan and Rest of Asia-Pacific in APAC; and the Middle East, Africa, and Latin America in LAMEA. The demand for organic food, personal care products and growing concerns about environmental-friendly agriculture products are expected to foster the growth of neem-based products, globally.

Key findings of the study:

• The world neem extract market is expected to exhibit significant growth during the forecast period owing to the growing awareness about the side effects of chemical-based personal care products, concerns regarding environmental degradation, and adoption of natural and herbal products to cure health diseases.
• In 2015, the agriculture segment accounted for 67.9% share of the overall neem extract market revenue.
• APAC is the highest revenue-generating segment and is likely to continue this trend throughout the forecast period.
• The personal care segment is expected to grow with a rapid CAGR of 19.6%
• Europe would be one of the most lucrative markets in terms of growth, registering a CAGR of 20.3% during 2016 - 2022.

Market players have increased their product offerings to cater to the need of consumers. Neem extracts are exported to different regions as the demand for natural and environmental-friendly products is rising. In 2014, AG Global, a U.S.-based organic fertilizer manufacturing company, signed an agreement with EID Parry India Ltd. to add neem products to its product line. This partnership enabled Parry to access AG Globals distribution channels across North America. The key companies profiled include E.I.D Parry India Ltd., Neeming Australia Pvt. Ltd., Bros India Group, Agro Extracts Limited, Parker India Group, Fortune Biotech Ltd., The Indian Neem Tree Company, Ozone Biotech, PJ Margo Pvt. Ltd., and Gramin India Agri BusiNest.

For more information Visit at: http://mrr.cm/JPk

Find all Pharmacy Reports at: http://www.marketresearchreports.com/pharmacy

World Medical Tourism Market is Expected to Reach $143.8 Billion by 2022; Finds New Report

World Medical Tourism Market - Opportunities and Forecasts, 2014 -2022, projects that the world medical tourism market would reach $143.8 billion by 2022, with a CAGR of 15.7% from 2015 to 2022. Cancer treatment would continue to be the highest revenue-generating segment throughout the forecast period. North America and Asia-Pacific are estimated to remain principal revenue-generating regions and collectively accounted for more than 60% of the global medical tourism market in 2015, in terms of revenue.

The major factors that boost the market growth include, affordability, availability, and accessibility of superior quality healthcare services with healthy support and assistance from tourism departments & local governments. In addition, increasing incidence of cancer and other serious ailments is anticipated to drive the demand for healthcare services, which in turn is expected to drive the world medical tourism market. Limited coverage and lengthy partial reimbursement offered by insurance companies along with difficulties associated with cross border travel, such as language barriers, connectivity, documentation, and Visa approval issues, are likely to restrict the market growth.

Cancer treatment segment would continue to lead the market throughout the analysis period owing to increase with the number of cross-border travelers seeking better cancer treatment. In addition, cancer treatment is expensive and prolonged, hence better treatment available at affordable prices motivates several patients to choose medical tourism. North America and Asia-Pacific are the major hosts for travelers seeking cancer treatment. Neurological treatment emerged as the fastest growing segment with a CAGR of 16.2%, in terms of revenue, during the forecast period. Neurological treatment requires high level of expertise and limited personnel with requisite expertise. Increasing number of people are diagnosed with neurological ailments, owing to their stressful lifestyles. This is anticipated to increase the number of medical tourists travelling to destinations for better neurological treatment.

Geographically, North America and Asia-Pacific dominated, and collectively accounted for two-thirds of the overall medical tourism market in 2015. The growth of these regions is attributed to the availability of affordable medical treatments for several disease conditions in countries such as Mexico, Thailand, Malaysia, India and Singapore. However, Asia-Pacific is the fastest growing region followed by LAMEA, owing to the increasing treatment success rates, coupled with the affordable price range. Within Asia-Pacific medical tourism market, India and Malaysia are few of the fastest growing countries.

Increase in reach of internet and various medical tourism associations such as Europe Medical Tourism Alliance (EuMTA) & Medical Tourism Association (MTA) along with medical travel agencies in the last decade, helped to raise awareness about the treatment options beyond the home country. Furthermore, several medical travel facilitators have emerged, such as Beijing Saint Lucia Consulting Ltd, Kangtai Health Network, Ryavo Healthcare, Medigo, PlacidWay, and government tourist associations of respective countries. These agencies provide assistance ranging from information about available treatments and their quality in various destinations to travel arrangements, accommodation, and post-treatment recovery.

Key findings of the study:

• In 2015, cancer treatment segment generated the highest revenue, accounting about one-third of the overall market revenue and is projected to grow at a CAGR of 16.0% during the forecast period.
• Neurological treatment segment is expected to grow at an above-average CAGR of 16.2%, owing to increased number of skilled medical personnel.
• North America accounted for about one-third of the global medical tourism in 2015. Mexico occupies the major market share within North America followed by the U.S.
• The Asia-Pacific region is anticipated to be the fastest growing medical tourism market during the analysis period, followed by LAMEA region.
• Thailand, Singapore, and India are the major shareholders in Asia-Pacific with a combined share of more than three fourth of the medical tourism market in the region.

Major market players have established overseas promotional offices to attract more medical tourists. Moreover, respective tourism departments promote their countries as center of excellence in specific healthcare services. Such strategic measures aid in increasing the number of medical tourists choosing to avail their healthcare services. Key service providers include Apollo Hospitals Enterprise Limited, Fortis Healthcare Ltd., Asian Heart Institute and Research Centre Private Limited, KPJ Healthcare Berhad, Barbados Fertility Centre, NTT Medical Center Tokyo, Seoul National University Hospital, UZ Leuven (University Hospitals Leuven), Infectious Diseases Partners Pte. Ltd., Aditya Birla Memorial Hospital, Barbados Fertility Centre, Prince Court Medical Centre, and Samitivej Public Company Limited.

For more information Visit at: http://mrr.cm/Jdt

Find all Medical Tourism Reports at: http://www.marketresearchreports.com/medical-tourism

Global Transplant Diagnostics Market to grow at a CAGR of 6.63% during the period 2016 - 2020; Finds New Report

Report forecast the global transplant diagnostics market to grow at a CAGR of 6.63% during the period 2016-2020.

Transplantation involves the transfer of cells, tissues, or organs from a donor to a recipient for restoring their function in cases of damage. Donor and recipient cells, tissues, and organs should match or be compatible, otherwise it can lead to transplant rejection. Human leukocyte antigens (HLAs) are present on the surface of the cells that regulate body recognition and reject foreign tissue transplants. In humans, major histocompatibility complex controlled by the genes located on chromosome 6 is responsible for ensuring compatibility between donors and recipients.

The report covers the present scenario and the growth prospects of the global transplant diagnostics market for 2016-2020. To calculate the market size, we consider the revenue generated from the sales of molecular and non-molecular assays. We also consider the revenue generated from pre- and post-transplant diagnostic products and accessories.

The market is divided into the following segments based on geography:

• Americas
• APAC
• EMEA

According to the report, a key growth driver is the public awareness of organ donation. Awareness of organ donation can help meet the demand for the number of required transplantation. In the US, a research study estimated that about 121,678 people are awaiting organ transplantation. The median waiting time for kidney transplantation is 3.6 years and can vary depending on the person's health, compatibility with donor organ, and availability of organ. The study also reported that over 3,000 new individuals are added to the waiting list for kidney transplant each month, of which about 13 people die each day while waiting for transplantation.

Further, the report states that one challenge that could restrict market growth is the limited technical expertise with regard to advanced transplant diagnostics.

Global Transplant Diagnostics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

key players in the global transplant diagnostics market: Bio-Rad Laboratories, CareDx, Illumina, Immucor, Linkage Biosciences, and Thermo Fisher Scientific.

Other Prominent Vendors in the market are: Abbott Laboratories, Becton Dickinson, Danaher, F. Hoffmann-La Roche, HistoGenetics, Ortho Clinical Diagnostics, Oxford Immunotec, Qiagen, Siemens, Sigma-Aldrich, and Tosoh Bioscience.

Market driver

• Public awareness of organ donation
• For a full, detailed list, view our report

Market challenge

• Limited technical expertise
• For a full, detailed list, view our report

Market trend

• Product approvals and launches
• For a full, detailed list, view our report

Key questions answered in this report

• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

Spanning over 81 pages and 51 Exhibit “Global Transplant Diagnostics Market 2016 - 2020” report covers Executive summary, Scope of the report, Market research methodology, Introduction, Market landscape, Market segmentation by screening, Market segmentation by product, Market segmentation by end-user, Market segmentation by application, Geographical segmentation, Market drivers, Impact of drivers, Market challenges, Impact of drivers and challenges, Market trends, Vendor landscape, Major vendors, Appendix.

For more information Visit at: http://mrr.cm/Jd7

Related Reports;

Global Anesthesia Laryngeal Masks Market 2016-2020 - Visit at - http://mrr.cm/Jd8

Global Ambulatory Blood Pressure Monitoring Market 2016-2020 - Visit at - http://mrr.cm/JdX

Global Osteoarthritis Pain Drugs Market to grow at a CAGR of 8.38% during the period 2016 - 2020; Finds New Report

Report forecast the global osteoarthritis pain drugs market to grow at a CAGR of 8.38% during the period 2016-2020.

Osteoarthritis, the most common type of arthritis, is a leading cause of disability. It is a chronic, progressive degenerative joint disease, which is characterized by gradual destruction of the articular cartilage, hypertrophy of the bone margins, and a series of biochemical and morphological changes in the synovial membrane and joint capsule. This results in pain and loss of movement.

It is also known as degenerative joint disease, hypertrophic arthritis, and degenerative arthritis, and is most commonly prevalent in older (above 60 years of age) and middle-aged people (between 40-59 years of age). The exact etiology of osteoarthritis is not well understood, but is believed to be an outcome of mechanical and molecular events in the affected joint.

Increasing age, obesity, overuse of the joint, weak thigh muscles, and genetics are some of the common risk factors. Treatment is given depending upon the affected joint, including the hand, wrist, neck, back, knee, and hip, and involves medication and exercise.

The report covers the present scenario and the growth prospects of the global osteoarthritis pain drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded, generic, and off-label drugs used to treat osteoarthritis pain. It also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market.

The market is divided into the following segments based on geography:

• Americas
• APAC
• EMEA

According to the report, a key driver of market growth is the high numbers of unmet medical needs. There are a number of unmet medical needs in this market due to the chronic nature of osteoarthritis and the absence of curative therapies. With drugs such as NSAID's, simple analgesics, corticosteroids, and opioids proving effective for individuals with early-to-mid stages of osteoarthritis pain, the competition in the market is strong. However, these options do not provide adequate pain relief in the late stages of osteoarthritis. Ultimately, effective treatment of osteoarthritis pain requires an improved anti-inflammatory molecule, which gives reason for R&D to develop new drugs with better MOA and minimal adverse effects. Thus, absence of effective and safe long-term treatment for creates numerous opportunities for pharmaceutical companies.

Further, the report states that one challenge that could restrict market growth is the consumer’s preference for alternate therapies.

Global Osteoarthritis Pain Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

key players in the Global Osteoarthritis Pain Drugs Market: Abbott Laboratories, Johnson & Johnson, Novartis International, and Pfizer.

Other Prominent Vendors in the market are: AbbVie, Abiogen Pharma, Afferent Pharmaceuticals, Astellas Pharma, BioDelivery Sciences International, CrystalGenomics, Cytori Therapeutics, Daiichi Sankyo, Eli Lilly, Endo Pharmaceuticals Holdings, Horizon Pharma, iCeutica, Iroko Pharmaceuticals, Merck, Nuvo Research, Regeneron Pharmaceuticals, Sanofi, SantoSolve, Techfields Pharma, Winston Pharmaceuticals, Yooyoung Pharmaceutical, and Zynerba Pharmaceuticals.

Market driver

• Significant unmet medical needs
• For a full, detailed list, view our report

Market challenge

• Preference for alternative therapies
• For a full, detailed list, view our report

Market trend

• Emergence of new treatments
• For a full, detailed list, view our report

Key questions answered in this report

• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

Spanning over 97 pages and 67 Exhibit “Global Osteoarthritis Pain Market 2016 - 2020” report covers Executive summary, Scope of the report, Market research methodology, Introduction, Market landscape, Disease overview, Pipeline portfolio, Osteoarthritis pain drugs: Clinical trials, Opportunities for research in osteoarthritis, Market landscape, Market segmentation by drug class, Market segmentation by ROA, Market segmentation by dosage form, Geographical segmentation, Market drivers, Impact of drivers, Market challenges, Impact of drivers and challenges, Market trends, Vendor landscape, Upcoming vendors with novel approaches, Appendix.

For more information Visit at: http://mrr.cm/Jda

Related Reports;

Global Pneumatic Nebulizers Market 2016-2020 - Visit at - http://mrr.cm/JdR

Global Regenerative Medicine Market 2016-2020 - Visit at - http://mrr.cm/JdD

World Mechanical Ventilators Market is Expected to Reach $3.9 Billion by 2022; Finds New Report

World Mechanical Ventilators Market -Opportunities and Forecasts, 2015 -2022, the world mechanical ventilators market is estimated to grow at a CAGR of 5.4% from 2016 to 2022. The intensive care mechanical ventilators segment accounted for around three-fourths of the market share in 2015, and is expected to dominate the overall market during the study period. North America and Europe, collectively, accounted for over half of the market share in 2015.

Major factors that contribute to the market growth include, adoption of mechanical ventilators to support treatment of chronic diseases, such as asthma, chronic obstructive pulmonary disease (COPD), bronchitis, lung cancer, and increasing number of intensive care unit (ICU) admissions of critically ill geriatric patients. Further, the shift in focus towards the use of portable or transport mechanical ventilators and rise in per capita healthcare spending is likely to supplement the market growth throughout the forecast period. On the other hand, factors such as high cost of mechanical ventilators and injuries associated with invasive ventilation restrict the market growth.

Intensive care mechanical ventilators segment dominated the market in 2015, and this growth is attributed to the increase in number of patients suffering from chronic diseases. The portable mechanical ventilators segment is projected to grow with the highest CAGR of 7.2% (Value terms) from 2016 to 2022. This is due to the growing adoption of easy-to-use portable mechanical ventilators among the geriatric patient population and the preference from invasive ventilation to non-invasive ventilation.

In 2015, the geriatric population was the highest revenue-generating segment and accounted for around 44% due to the rise in the aged population prone to chronic respiratory diseases. However, the pediatric and neonatals segment is likely to register a fastest growing CAGR of 7.1% (Value terms) during the forecast period. The growth of this segment is caused due to rise in incidence of neonatal mortality and need of convenient ventilation facilities for newborn and premature babies.

Key findings:

• Pediatric/neonatal and adults segment, collectively, accounted for more than half of the overall mechanical ventilators market in 2015.
• The invasive mechanical ventilators segment is expected to maintain its foothold in the market throughout the forecast period; however, the non-invasive ventilator is estimated to be the fastest growing segment.
• Asia-Pacific is expected to be one of the fastest growing markets, both in terms of value and volume, growing at a CAGR of 6.1% and 4.4%, respectively, from 2016 to 2022.
• In 2015, the U.S. was the largest revenue generating country; however, Canada registered the fastest growing CAGR of 7.7% (Value terms) during the forecast period.
• The U.K. is projected to be the fastest growing country with a CAGR of 6.7% (Value terms) from 2016 to 2022.

Asia-Pacific would continue to dominate the market throughout the analysis period. This is mainly attributed to the large number of ICU beds, huge patient population in the need of ventilation, increasing prevalence of diseases such as respiratory disease and cancer, rising demand of advanced healthcare facilities along with improving infrastructure and growing in-bound medical tourism in this region. Moreover, Asia-Pacific is also anticipated to be the fastest growing region, registering a CAGR of 6.1% during the forecast period.

The key companies profiled in this report include, Mindray Medical International Limited, Becton Dickinson and Company (CareFusion), Philips Healthcare, Carl Reiner Gmbh, Getinge Group (Maquet), Draegerwerk AG & Co. KGaA (Drager), General Electric Company (GE Healthcare), Hamilton Medical AG, Covidien (Medtronic, Inc.), and Smiths Group Plc (Smiths-Medical).

For more information Visit at: http://mrr.cm/Jdm

Find all Medical Devices Reports at: http://www.marketresearchreports.com/medical-devices